Mogam Lab Logo

Board of Directors

Board meeting

The MOGAM Board of Directors is composed of experts who guide the direction of the institute, based on extensive experience and deep insights in their respective fields. Through key decision-making, we present the future of MOGAM to fulfill our mission of 'AI-driven innovative drug development' and realize the public interest values of a non-profit foundation.

Greetings
Il-Sup Huh

MOGAM Institute for Biomedical Research is a private non-profit research foundation established to contribute to innovative pharmaceutical development based on scientific understanding of diseases and drugs, and to help those suffering from diseases.

The starting point of our institute was the funds donated in 1984 based on the domestic and international success of the hepatitis B vaccine, which Green Cross (GC) developed as the third in the world. Over the past 40 years, the institute has accumulated the knowledge, methodologies, and data-based capabilities necessary for new drug development, contributing to the advancement of the domestic bio-pharmaceutical field. The 40th anniversary of our founding in 2024 was a turning point for newly defining our future role based on this accumulation. New drug development is now moving to a new paradigm with the combination of data and artificial intelligence. MOGAM Institute for Biomedical Research has been actively transitioning to an AI-based new drug development research institute since 2022, focusing on computer-based research to strengthen the role of increasing the precision and speed of new drug development decision-making through data and models. Going forward, MOGAM Institute for Biomedical Research will continue to serve as a bridge between domestic and international academia and industry based on open innovation, and will continue AI-integrated new drug development research. With the mindset of sharing the suffering of even one patient, we will continue our efforts to fight diseases that threaten the healthy lives of humanity. Thank you.

Chairman, MOGAM Institute for Biomedical Research
Il-Sup Huh

Dong-Jip Kim

MOGAM Institute for Biomedical Research is opening the era of AI drug development.

Since its founding in 1984, MOGAM Institute for Biomedical Research has established important milestones that present the direction that Korean life science and new drug development research should take. Now, we are embarking on a new challenge to connect AI and life science based on our long research experience and accumulated scientific achievements. AI is already rapidly changing our daily lives and society as a whole. However, properly utilizing AI in new drug development to lead to actual treatments remains a significant challenge. This is because it requires not only a deep understanding of life phenomena, but also data science capabilities to handle and interpret vast amounts of data, and experience in the actual new drug development process. To this end, MOGAM Institute for Biomedical Research is nurturing researchers with expertise and field experience in various fields, and is devoting all its efforts to successfully connecting AI-based research to new drug development. In particular, we are focusing on research that actually solves problems that have not been solved for a long time in the new drug development process, not just using AI as a simple tool. All members of the institute, including myself, will do our best in AI-based new drug development research so that suffering from diseases can be reduced and more people can enjoy healthy lives. Also, as a non-profit research foundation with the founding philosophy of contributing to society, we will become an open research arena where academia, hospitals, and industry can naturally connect to create greater change. We will do our best to ensure that the research of MOGAM Institute for Biomedical Research extends beyond the laboratory to the health and future of society as a whole.

Director, MOGAM Institute for Biomedical Research
Dong-Jip Kim
Executives

We introduce the people who have led the direction of research based on MOGAM's vision and philosophy.

Il-Sup Huh

Il-Sup Huh

Chairman, Board
  • (Current) Chairman, GC
  • (Former) Chairman, Korea Pharmaceutical and Bio-Pharma Manufacturers Association
  • (Former) Executive Director, Hanil Cement Co., Ltd.
Dong-Jip Kim

Dong-Jip Kim

Director, Board
  • (Current) Professor Emeritus, The Catholic University of Korea
  • (Former) President, Korea Hematopoietic Stem Cell Bank Association
  • (Former) Director, Yeouido St. Mary's Hospital
Young-Bok Chae

Young-Bok Chae

Director, Board
  • (Current) Chairman, Wonjeong Research Institute
  • (Former) Minister of Science and Technology
  • (Former) Chairman, Institut Pasteur Korea
Kwang-Soon Shin

Kwang-Soon Shin

Director, Board
  • (Former) Professor, College of Veterinary Medicine, Chungnam National University
  • (Former) Director, GC Green Cross Central Research Institute
In-Soon Han

In-Soon Han

Director, Board
  • (Former) Vice President, MG Academic Development Division
  • (Former) Executive Director, GC Green Cross Academic Development Division
Young-Joo Bang

Young-Joo Bang

Director, Board
  • (Current) CEO, Bang Young-joo Consulting
  • (Former) Professor, Seoul National University College of Medicine
Doo-Hong Park

Doo-Hong Park

Director, Board
  • (Current) CTO, Mirae Advance Life Sciences
  • (Former) Director, National Anticancer Drug Development Project Bio-drug Division
  • (Former) Director, GC Green Cross Central Research Institute
Chan-Hee Lee

Chan-Hee Lee

Director, Board
  • (Former) Professor of Microbiology, Chungbuk National University
Eun-Chul Huh

Eun-Chul Huh

Director, Board
  • (Current) CEO, GC Green Cross
  • (Former) Director, MOGAM Institute for Biomedical Research
Hyun-Jin Shin

Hyun-Jin Shin

Director, Board
  • (Current) Director, MOGAM Institute for Biomedical Research
  • (Former) Director, AI Drug Development Team, R&D Division, GC Green Cross
Chan-Seop Kim

Chan-Seop Kim

Auditor, Board
  • (Current) CPA, Seowoo Accounting Corporation
  • (Current) CEO, Samji Accounting Corporation